- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Mike Boken, Shire
S
Mike Boken
Senior Director of Marketing, Vyvanse, Shire
BIG DEAL: Launching Prevnar, the first blockbuster vaccine
SUCCESS IS: 1 million Vyvanse scripts written 10 months after launch
You have to find a way to make your drug stand out from everybody else," says Mike Boken. He speaks from experience: Standing 7 feet tall, he never gets lost in the crowd.
Mike Boken
There's another truism that Boken lives by. As one of nine brothers and sisters, his mother expected chores to be done right—or else. "What I remember is that if you do it right the first time, you'll be in a better place."
Boken has applied that philosophy to promotion of Adderall XR and its ADHD follow up Vyvanse by developing smart adherence programs that keep patients on drug the first time around. It turns out that what's best for the patient is also best for the company: "We've seen the best ROIs coming from those retention programs."
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
